the Number of interruptions that occurred during the procedure
Dexmedetomidine Compared to Ketofol for Sedation in Paediatrics
Brief Summary
Dental fear and anxiety remain common problems that should be managed by both the dentist and the anesthetist. The currently available evidence for safe and effective sedative drugs for children undergoing the dental procedure is scarce The aim of this study was to compare the safety and efficacy of intravenous ketofol versus dexmedetomidine (Dex) as premedications a sedative in anxious children undergoing dental pulp therapy
Intervention / Treatment
The study participants will be allocated into two equal groups. Subjects in group I will receive ketofol solution (ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h. Subjects in group II will receive the Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h. Non-invasive blood pressure (mean ABP) peripheral oxygen saturation, heart rate, and respiratory rate will be assessed at baseline, at 2 minutes, then at 5 minutes intervals till 60 minutes. Ramsay sedation and Aldrete's recovery rating scores were assessed before, during, and after the procedure.
-
Ketamine/ propofol (DRUG)ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
-
Dexmedetomidine (DRUG)Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
Condition or Disease
- Vital Signs
Phase
Study Design
Study type: | INTERVENTIONAL |
---|---|
Status: | Completed |
Study results: | No Results Available |
Age: | 5 Years to 10 Years |
Enrollment: | 40 (ACTUAL) |
Allocation: | Randomized |
Primary Purpose: | Supportive Care |
MaskingThe pedo-dentist, the independent observer/data collector, and participants will be blind to the type of intervention. The study drugs will be prepared by an anesthesiologist who will not participate in the observation of the data. All the lines and syringes will be wrapped to mask colors of the sedative drugs, and the syringes will be label coded. QUADRUPLE:
|
Clinical Trial Dates
Start date: | Oct 10, 2020 | ACTUAL |
---|---|---|
Primary Completion: | Dec 10, 2021 | ACTUAL |
Completion Date: | Dec 30, 2021 | ACTUAL |
Study First Posted: | Dec 21, 2020 | ACTUAL |
Last Updated: | Aug 04, 2022 |
Sponsors / Collaborators
Lead Sponsor:
Ain Shams University
Responsible Party:
N/A
This double-blind, parallel-group, randomized clinical study will recruiter anxious children who will undergo dental pulp therapy. The study participants will be allocated into two equal groups. Subjects in group I will receive ketofol solution (ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h. Subjects in group II will receive the Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h. Non-invasive blood pressure (mean ABP), peripheral oxygen saturation, heart rate, and respiratory rate will be assessed at baseline, at 2 minutes, then at 5 minutes intervals till 60 minutes. Ramsay sedation and Aldrete's recovery rating scores will be assessed before, during, and after the procedure.
Participant Groups
-
ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.
-
A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h.
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 5 |
Maximum Age: | 10 |
Age Groups: | Child |
Healthy Volunteers: | Yes |
Inclusion Criteria:
* ASA-I children,
* aged 5-10 years-old,
* requiring dental pulp therapy
Exclusion Criteria:
* ASA class ≥ II;
* previous experience with GA or Conscious sedation (CS);
* dental treatment expected to exceed 45 minutes;
* history of allergy to local anesthetics, Dex, propofol, ketamine, eggs, or soya;
* respiratory tract infections
* ASA-I children,
* aged 5-10 years-old,
* requiring dental pulp therapy
Exclusion Criteria:
* ASA class ≥ II;
* previous experience with GA or Conscious sedation (CS);
* dental treatment expected to exceed 45 minutes;
* history of allergy to local anesthetics, Dex, propofol, ketamine, eggs, or soya;
* respiratory tract infections
Primary Outcomes
Secondary Outcomes
-
total dose of rescue propofol in mg
More Details
NCT Number: | NCT04678050 |
---|---|
Other IDs: | IRB 000-6379 |
Study URL: | https://clinicaltrials.gov/study/NCT04678050 |
Last updated: Sep 29, 2023